Affiliation:
1. Department of Biochemistry and Microbiology, Tishreen University, Latakia – Syria.
2. AlHawash Private University, Homs, Syria.
3. Al-Andalus University for Medical Sciences, Tartous, Syria.
4. Assistant Professor, Department of Oncology and Hematology, Tishreen University Hospital Latakia – Syria.
Abstract
The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene mutations can reduce the activity of the enzyme, which has been shown to be a significant factor in the risk of developing certain types of cancer and numerous other diseases, including cardiovascular conditions, diabetes, ischemia, venous thrombosis, hypotonia, and many others. This study aims to determine the frequency of the two most prevalent MTHFR gene polymorphisms, C677T and A1298C, in the Syrian coastal population. Real-time PCR is used to detect MTHFR gene variants in samples from seventy healthy males from Syrian Coastal Area. The frequency of the C/C, C/T, and T/T genotypes for the C677T polymorphism was 47.14 percent, 38.57 percent, and 14.29 percent, respectively. The overall carrier rate was 52.86%, and the allelic frequency was 0.336. The genotypic prevalence of A/A, A/C, and C/C for the A1298C polymorphism was 44.29%, 35.71%, and 20%, respectively, with an allelic frequency of 0.378, while the overall carrier rate was 55.71%. In conclusion, the high prevalence of the MTHFR A1298C polymorphism is a significant finding that must be investigated in terms of clinical implications and reveals an additional genetic trait unique to the Syrian coast population.
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference56 articles.
1. Arruda VR, Siqueira LH, Gonçalves MS, Von Zuben PM, Soares MCP, Menezes R, Annichino-Bizzacchi JM, Costa FF. Prevalence of the mutation C677 → T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998; 78:332–335; doi: 10.1002/(sici)1096-8628(19980724)78:4<332::aid-ajmg5>3.0.co;2-n
2. Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodríguez-Maldonado J, Duconge J, Ruaño G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019; 13:649–661; doi: 10.2217/bmm-2018-0392
3. Dean L. Methylenetetrahydrofolate Reductase Deficiency. Med. Genet. Summ. 2016; Bookshelf ID: NBK66131
4. Sandeep Goyal, V.K. Bansal, Dhruba Sankar Goswami, Suresh Kumar. sVascular Endothelial Dysfunction: Complication of Diabete Mellitus and Hyperhomocysteinemia. Research J. Pharm. and Tech. 2010; 3 (3): 657-664.
5. Izmirli M. A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk. Mol Biol Reports. 2012; 40:625–637; doi: 10.1007/s11033-012-2101-2